Hepatotoxicity epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Megan Merlo (talk | contribs) No edit summary |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatotoxicity}} | {{Hepatotoxicity}} | ||
{{CMG}} | {{CMG}} {{AE}} {{JH}} | ||
{{PleaseHelp}} | |||
==Overview== | ==Overview== | ||
Drug-related hepatotoxicity is generally considered as an uncommon complication for many drugs, with an incidence between 1 in 10,000 and 1 in 100,000.<ref name="Navarro-2006">{{Cite journal | last1 = Navarro | first1 = VJ. | last2 = Senior | first2 = JR. | title = Drug-related hepatotoxicity. | journal = N Engl J Med | volume = 354 | issue = 7 | pages = 731-9 | month = Feb | year = 2006 | doi = 10.1056/NEJMra052270 | PMID = 16481640 }}</ref> The incidence of | Drug-related hepatotoxicity is generally considered as an uncommon complication for many drugs, with an incidence between 1 in 10,000 and 1 in 100,000.<ref name="Navarro-2006">{{Cite journal | last1 = Navarro | first1 = VJ. | last2 = Senior | first2 = JR. | title = Drug-related hepatotoxicity. | journal = N Engl J Med | volume = 354 | issue = 7 | pages = 731-9 | month = Feb | year = 2006 | doi = 10.1056/NEJMra052270 | PMID = 16481640 }}</ref> The true incidence of drug-induced liver injury is hard to determine, partly because of difficulties in detection as well as lack of unified criteria for diagnosis. | ||
==Epidemiology and Demographics== | |||
Drug-induced liver injury (DILI) has an approximate annual incidence between 10 and 15 per 10,000 to 100,000 persons. One study from France reported a crude annual incidence of 13.9 ± 2.4 per 100,000 inhabitants, which is 16 times greater than the number noted by spontaneous reporting to French regulatory authorities.<ref name="Sgro-2002">{{Cite journal | last1 = Sgro | first1 = C. | last2 = Clinard | first2 = F. | last3 = Ouazir | first3 = K. | last4 = Chanay | first4 = H. | last5 = Allard | first5 = C. | last6 = Guilleminet | first6 = C. | last7 = Lenoir | first7 = C. | last8 = Lemoine | first8 = A. | last9 = Hillon | first9 = P. | title = Incidence of drug-induced hepatic injuries: a French population-based study. | journal = Hepatology | volume = 36 | issue = 2 | pages = 451-5 | month = Aug | year = 2002 | doi = 10.1053/jhep.2002.34857 | PMID = 12143055 }}</ref> The true incidence of hepatic adverse events in the general population remains unknown and is often underestimated. | |||
More than a thousand drugs have been associated with DILI, the most common among them are antimicrobial agents, central venous system medications, and herbal supplements. Women were found to be more prone to developing DILI than men.<ref name="Chalasani-2008">{{Cite journal | last1 = Chalasani | first1 = N. | last2 = Fontana | first2 = RJ. | last3 = Bonkovsky | first3 = HL. | last4 = Watkins | first4 = PB. | last5 = Davern | first5 = T. | last6 = Serrano | first6 = J. | last7 = Yang | first7 = H. | last8 = Rochon | first8 = J. | last9 = Chalasani | first9 = N. | title = Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. | journal = Gastroenterology | volume = 135 | issue = 6 | pages = 1924-34, 1934.e1-4 | month = Dec | year = 2008 | doi = 10.1053/j.gastro.2008.09.011 | PMID = 18955056 }}</ref> | |||
It has been suggested that for every 10 cases of elevations in [[alanine aminotransferase|alanine aminotransferase (ALT)]] in a clinical trial, there will be at least one case of severe DILI that develops once the drug becomes widely available.<ref name="Maddur-2011">{{Cite journal | last1 = Maddur | first1 = H. | last2 = Chalasani | first2 = N. | title = Idiosyncratic drug-induced liver injury: a clinical update. | journal = Curr Gastroenterol Rep | volume = 13 | issue = 1 | pages = 65-71 | month = Feb | year = 2011 | doi = 10.1007/s11894-010-0154-8 | PMID = 21049293 }}</ref><ref name="Lewis-2006">{{Cite journal | last1 = Lewis | first1 = JH. | title = 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. | journal = Pharmacoepidemiol Drug Saf | volume = 15 | issue = 4 | pages = 221-9 | month = Apr | year = 2006 | doi = 10.1002/pds.1209 | PMID = 16444771 }}</ref> | It has been suggested that for every 10 cases of elevations in [[alanine aminotransferase|alanine aminotransferase (ALT)]] in a clinical trial, there will be at least one case of severe DILI that develops once the drug becomes widely available.<ref name="Maddur-2011">{{Cite journal | last1 = Maddur | first1 = H. | last2 = Chalasani | first2 = N. | title = Idiosyncratic drug-induced liver injury: a clinical update. | journal = Curr Gastroenterol Rep | volume = 13 | issue = 1 | pages = 65-71 | month = Feb | year = 2011 | doi = 10.1007/s11894-010-0154-8 | PMID = 21049293 }}</ref><ref name="Lewis-2006">{{Cite journal | last1 = Lewis | first1 = JH. | title = 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. | journal = Pharmacoepidemiol Drug Saf | volume = 15 | issue = 4 | pages = 221-9 | month = Apr | year = 2006 | doi = 10.1002/pds.1209 | PMID = 16444771 }}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
{{WS}} | |||
{{WH}} | |||
Latest revision as of 19:20, 15 July 2016
|
Hepatotoxicity Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatotoxicity epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatotoxicity epidemiology and demographics |
|
Risk calculators and risk factors for Hepatotoxicity epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Drug-related hepatotoxicity is generally considered as an uncommon complication for many drugs, with an incidence between 1 in 10,000 and 1 in 100,000.[1] The true incidence of drug-induced liver injury is hard to determine, partly because of difficulties in detection as well as lack of unified criteria for diagnosis.
Epidemiology and Demographics
Drug-induced liver injury (DILI) has an approximate annual incidence between 10 and 15 per 10,000 to 100,000 persons. One study from France reported a crude annual incidence of 13.9 ± 2.4 per 100,000 inhabitants, which is 16 times greater than the number noted by spontaneous reporting to French regulatory authorities.[2] The true incidence of hepatic adverse events in the general population remains unknown and is often underestimated.
More than a thousand drugs have been associated with DILI, the most common among them are antimicrobial agents, central venous system medications, and herbal supplements. Women were found to be more prone to developing DILI than men.[3]
It has been suggested that for every 10 cases of elevations in alanine aminotransferase (ALT) in a clinical trial, there will be at least one case of severe DILI that develops once the drug becomes widely available.[4][5]
References
- ↑ Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. (2002). "Incidence of drug-induced hepatic injuries: a French population-based study". Hepatology. 36 (2): 451–5. doi:10.1053/jhep.2002.34857. PMID 12143055. Unknown parameter
|month=ignored (help) - ↑ Chalasani, N.; Fontana, RJ.; Bonkovsky, HL.; Watkins, PB.; Davern, T.; Serrano, J.; Yang, H.; Rochon, J.; Chalasani, N. (2008). "Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States". Gastroenterology. 135 (6): 1924–34, 1934.e1–4. doi:10.1053/j.gastro.2008.09.011. PMID 18955056. Unknown parameter
|month=ignored (help) - ↑ Maddur, H.; Chalasani, N. (2011). "Idiosyncratic drug-induced liver injury: a clinical update". Curr Gastroenterol Rep. 13 (1): 65–71. doi:10.1007/s11894-010-0154-8. PMID 21049293. Unknown parameter
|month=ignored (help) - ↑ Lewis, JH. (2006). "'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective". Pharmacoepidemiol Drug Saf. 15 (4): 221–9. doi:10.1002/pds.1209. PMID 16444771. Unknown parameter
|month=ignored (help)